Abstract
Regulated intravenous doses of quinidine were given to patients with the antibody of quinidine purpura to produce controlled thrombocytopenia without clinical sequelae. The degree of thrombocytopenia and the rate at which it developed were dependent on the relative plasma concentration of quinidine and antibody. By relating in vivo changes in platelet levels to concurrent in vitro tests for antibody activity and to quantitative relationships between reactants determined in Papers I and III of this series, it was concluded that the amount of antibody which attaches to platelets when thrombocytopenia develops is insufficient to cause complement fixation or platelet agglutination. Platelets do not appear to be destroyed directly by reaction with antibody in vivo. The minimal amount of antibody which does attach to platelets in vivo appears to increase their susceptibility to the usual mechanisms of sequestration. Megakaryocytes and blood vessels do not appear to be affected directly by the antibody which causes quinidine purpura, and hemorrhagic manifestations of the disease appear to be consequent to changes in platelets alone. A safe method of performing in vivo tests for the presence of an antibody of drug purpura is described. The implications of the present work in idiopathic thrombocytopenic purpura are discussed.
Full Text
The Full Text of this article is available as a PDF (1.1 MB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- ACKROYD J. F. The pathogenesis of thrombocytopenic purpura due to hypersensitivity to sedormid. Clin Sci. 1949 Apr;7(3-4):249–285. [PubMed] [Google Scholar]
- ARIMURA G., HARRINGTON W. J., MINNICH V. The autoimmune thrombocytopenias. Prog Hematol. 1956;1:166–192. [PubMed] [Google Scholar]
- BLOCH E. H. The in vivo microscopic vascular anatomy and physiology of the liver as determined with the quartz rod method of transillumination. Angiology. 1955 Aug;6(4):340–349. doi: 10.1177/000331975500600406. [DOI] [PubMed] [Google Scholar]
- BOLTON F. G., DAMESHEK W. Thrombocytopenic purpura due to quinidine. I. Clinical studies. Blood. 1956 Jun;11(6):527–546. [PubMed] [Google Scholar]
- BOUNAMEAUX Y., LECOMTE J. Plaquettes et reaction antigene-anticorps in vitro. Acta Allergol. 1955;9(4):288–296. [PubMed] [Google Scholar]
- CRADDOCK C. G., Jr, ADAMS W. S., PERRY S., LAWRENCE J. S. The dynamics of platelet production as studied by a depletion technique in normal and irradiated dogs. J Lab Clin Med. 1955 Jun;45(6):906–919. [PubMed] [Google Scholar]
- CREGER W. P., TULLEY E. H., HANSEN D. G. A note on the effect of hydrocortisone on the microelectrophoretic characteristics of human red cell-antibody unions. J Lab Clin Med. 1956 May;47(5):686–690. [PubMed] [Google Scholar]
- DITLEFSEN E. M. Concentrations of quinidine in blood following oral, parenteral and rectal administration. Acta Med Scand. 1953;146(2):81–92. doi: 10.1111/j.0954-6820.1953.tb10216.x. [DOI] [PubMed] [Google Scholar]
- IZAK G., NELKEN D. Studies on thrombopoiesis. II. Thrombocytopoiesis in vitro from the bone marrow of patients with idiopathic thrombocytopenic purpura. Blood. 1957 Jun;12(6):520–528. [PubMed] [Google Scholar]
- MOODIE G. Thrombocytopenic purpura due to quinidine. Br Med J. 1950 Sep 2;2(4678):553–554. doi: 10.1136/bmj.2.4678.553. [DOI] [PMC free article] [PubMed] [Google Scholar]